RxDoctor Payments Data

Kim Kahler, APRN

Acute Care · Goshen, INNPI 1346338589

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 189 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.

$3,237in general payments, 2019–2025

Across 189 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$689
  • Pfizer$469
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$460
  • Boston Scientific$238
  • E.r. Squibb & Sons, L.L.C.$217
  • Merck$173
  • plus $990 from 18 others

What the payments were for

  • Food & beverage$3,237100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,237 in reported general payments places this provider in the 85th percentile of 240 acute care providers in Indiana.

See all acute care providers in Indiana

Medicare billing

Part B allowed, 2024
$57,377
Medicare patients
420
Services billed
1,146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$321,133
XareltoRivaroxaban42$59,191
EntrestoSacubitril/Valsartan37$50,488
Repatha SureclickEvolocumab30$17,053
Ranolazine ErRanolazine105$15,881
ZubsolvBuprenorphine Hcl/Naloxone Hcl22$5,830
Propafenone Hcl63$3,669
Metoprolol Succinate332$3,141
ClopidogrelClopidogrel Bisulfate283$2,187
Diltiazem 24hr Er (Cd)Diltiazem Hcl100$2,103
Atorvastatin Calcium276$1,876
Isosorbide Mononitrate ErIsosorbide Mononitrate192$1,530
Amiodarone Hcl65$1,388
Warfarin Sodium150$1,195
Potassium Chloride68$1,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$469$321,133236 claims
Johnson & JohnsonXarelto$45$59,19142 claims
NovartisEntresto$689$50,48837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 240 acute care providers in Indiana.

Other acute care in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →